Frequency and Severity of Hypoglycemia Under Conditions of Increased Hypoglycemic Risk with Insulin Efsitora Alfa Versus Insulin Glargine Treatment in Participants with Type 2 Diabetes-Reference-Cited by-同舟云学术

Frequency and Severity of Hypoglycemia Under Conditions of Increased Hypoglycemic Risk with Insulin Efsitora Alfa Versus Insulin Glargine Treatment in Participants with Type 2 Diabetes

Published:2024-06-22 Issue:8 Volume:15 Page:1785-1797
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Heise Tim,Andersen Grit,Pratt Edward J.^ORCID,Leohr Jennifer,Fukuda Tsuyoshi,Wang Qianqian,Kazda Christof,Bue-Valleskey Juliana M.,Bergenstal Richard M.

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13300-024-01605-7.pdf

Reference11 articles.

1. Rubin RR, Peyrot M, Kruger DF, Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ. 2009;35(6):1014–22.

2. Moyers JS, Hansen RJ, Day JW, Dickinson CD, Zhang C, Ruan X, et al. Preclinical characterization of LY3209590, a novel weekly basal insulin Fc-fusion protein. J Pharmacol Exp Ther. 2022;382(3):346–55.

3. Heise T, Chien J, Beals JM, Benson C, Klein O, Moyers JS, et al. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes Obes Metab. 2023;25(4):1080–90.

4. Bue-Valleskey JM, Kazda CM, Ma C, Chien J, Zhang Q, Chigutsa E, et al. Once-weekly basal insulin fc demonstrated similar glycemic control to once-daily insulin degludec in insulin-naive patients with type 2 diabetes: a phase 2 randomized control trial. Diabetes Care. 2023;46(5):1060–7.

5. Frias J, Chien J, Zhang Q, Chigutsa E, Landschulz W, Syring K, et al. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study. Lancet Diabetes Endocrinol. 2023;11(3):158–68.